Low Prevalence of Cryptococcal Antigenemia among Patients Infected with HIV/AIDS in Haiti

Frantz Jean Louis1*, Jocelyne Alboth Andre2, Georges Perrin1, Jean Wysler Domercant1, Kesner Francois3, Daniella Azor2, Josiane Buteau2, Jacques Bony3, Robert Burris1, David W Lowrance1 and Barbara J Marston2

1Centers for Disease Control and Prevention, Port-au-Prince, Haiti
2Government of Haiti, Port-au-Prince, Haiti
3Centers for Disease Control and Prevention, Atlanta, Georgia, USA

Abstract
Cryptococcal meningitis is a common opportunistic infection among persons with advanced HIV-associated immunosuppression and is associated with high mortality. The prevalence of asymptomatic cryptococcal antigenemia (CrAg) can inform the potential utility of screening and pre-emptive treatment prevention strategies. We assessed CrAg prevalence in a cohort of patients infected with HIV at 28 health facilities from February to September 2014 in order to inform Haitian national clinical guidelines. Of 13,000 patients that underwent CD4 cell count, 1,025 (7.9%) had a count ≤200 cells/mm³. Of these, 11 (1.1%) were CrAg positive. The CrAg positivity rate among patients with CD4 cell counts <100 cell/mm³ was 1.8%. Patients with CD4 cell counts <50 cells/mm³ had the highest CrAg rate (2.3%). CrAg prevalence was low but still warranted a CrAg screening and pre-emptive therapy approach for people infected with HIV with CD4 cell counts <100 cell/mm³ in Haiti.

Keywords: Cryptococcal meningitis; Cryptococcal antigen; Lateral flow assay; CD4 cell count; Test and treat

Introduction
Cryptococcosis usually manifests as meningitis (CM) and is generally seen in persons with advanced HIV infection and CD4 cell counts <200 cells/mm³ [1]. Global estimates suggest that there were about 1 million new cases and at least 500,000 deaths worldwide due to HIV-associated cryptococcosis in 2009 [2]. In developing countries, clinical outcomes are very poor for persons with CM, even when the best available therapy is provided [1,3-5]. Cryptococcosis accounts for between 13% and 44% of deaths among people living with HIV (PLHIV) in resource-limited countries (RLC) [4,6,7]. Limited information is available on the prevalence of cryptococcosis in the Latin American and Caribbean region. The only population-based estimated incidence of cryptococcosis in the Caribbean, reported in 2007, assumed the incidence in the Caribbean to be the same as in Latin America (3.4% per year) [2]. In 2000, Deschamps et al., found a prevalence of CM of 4% in a small cohort of 42 patients infected with HIV in Haiti [8].

Early detection and treatment may be the most cost-effective and easily implemented approach to improve clinical outcomes of CM [9]. Overt cryptococcosis is frequently preceded by asymptomatic cryptococcal infection, which is easily diagnosed by detection of cryptococcal antigen (CrAg) in the serum or cerebrospinal fluid (CSF). Asymptomatic antigenemia has been documented in 4-12% of PLHIV (CD4 cell counts <200 cells/mm³) within health facilities providing ART [5,10,11]. A substantial proportion of patients with asymptomatic antigenemia later develop overt CM or other evidence of systemic disease, even when ART is provided [11,12]. CrAg is detectable in serum a median of three weeks before the onset of CM symptoms [7]. CrAg screening can help identify individuals who would benefit from pre-emptive treatment of cryptococcal infection prior to ART initiation [13]. A FDA-approved lateral flow immunosassay (LFA) (Immuno-Mycologics, Inc., Norman, OK, USA; ABACUS ALS, Australia) to detect CrAg in serum and plasma has been widely used with reported high sensitivity and specificity [14]. Routine screening of asymptomatic patients with CD4 cell counts <100 cells/mm³ at ART initiation coupled with preemptive therapy for positive CrAg in Cambodia and Kenya was shown to be cost-effective in reducing the incidence of cryptococcosis, preventing CM and increasing life expectancy [11,15].

The World Health Organization (WHO) recommends to consider the implementation of CrAg screening and pre-emptive anti-fungal therapy in patients with a positive test among pre-ART adults with a CD4 cell count <100 cell/mm³ in areas with a prevalence of cryptococcal disease >3% (conditional recommendation, low-quality evidence)[16,17]. Studies on cost-effectiveness of a test and treat approach have found such an intervention effective even at prevalence levels as low as 0.6% [9,11,18]. To inform national application of international normative guidance, it was essential to define the burden of cryptococcal infection during the current phase of HIV treatment scale-up. This is particularly relevant as a substantial proportion of CM has been shown to occur among patients already receiving ART [19,20] in RLC.

In this study, we sought to determine the prevalence of CrAg among PLHIV during routine HIV care and treatment enrollment and monitoring visits in Haiti.

Methods
Study design and patient selection
We performed a cross sectional study of patients with advanced HIV (CD4 cell counts <200 cells/mm³) within health facilities providing HIV care and treatment across five of the 10 administrative departments...
Laboratory testing

A blood sample was obtained from each study participant and sent to a hub for CD4 testing. Every sample with a CD4 count <200 cells/mm\(^3\) was reflex tested for cryptococcal antigen using the IMMycoplasma Cryptococcal lateral flow assay (LFA), according to the manufacturer’s instructions for serum and CSF [14]. In summary, one drop of LFA specimen diluent, then 40 µL of specimen were added to a disposable test tube and mixed. Subsequently, a CrAg LFA test strip was inserted into the tube and read at 1-min intervals for up to 10 minutes. A single control line indicated a valid negative test and a control and test line indicated a valid positive test. All positive samples and 10% of negative samples were retested by technicians at the Haitian National Public Health Laboratory for quality control.

Data analysis

CrAg positivity rates, at different CD4 thresholds (<50, 50-100, <100, 100-200) and ART status was analyzed using SPSS (SPSS, v20.0 Chicago, IL: SPSS Inc.). Bivariate and multivariable logistic regression analyses were performed to assess risk factors for positive CrAg. Predictive factors such as gender, age, ART status and CD4 level were analyzed by stepwise regression with forward entry of variables. A p value <0.05 was considered statistically significant.

Ethics statement

Informed consent was obtained from all study participants and the study was approved by the Institutional Review Boards of the Haitian Ministry of Health and the U.S. Centers for Disease Control and Prevention. All samples were de-identified of personal identifiers for data entry and analysis.

Results

From February to September 2014, a total of 13,000 patients presenting for enrollment or follow-up at the 28 selected health facilities were tested for CD4 cell counts, of which 1,025 (7.9%) had a CD4 cell count <200 cells/mm\(^3\). Forty-one percent (399/982) were male, and 41% (399/982) were female. CD4 cell counts <50 cells/mm\(^3\) were tested for CrAg. Patients previously treated for cryptococcal infection in the three months preceding enrollment or currently taking an antifungal agent were excluded from study. Demographic data and tests results (CD4 and CrAg) were collected using a standardized form.

of Haiti (West, North, Nippes, Artibonite and South). Laboratories with adequate physical and electrical infrastructure in the selected departments had been established as testing hubs for decentralized CD4 testing for surrounding laboratories with less capacity [21]; these hubs also served as CrAg testing hubs for this study. Pre-ART and ART adults (≥18 years old) were enrolled during routine visits at 28 health facilities from February to September 2014. CD4 cell counts were measured at the testing hubs. Patients with CD4 cell count ≤200 cells/mm\(^3\) were tested for CrAg. Patients previously treated for cryptococcal infection in the three months preceding enrollment or currently taking an antifungal agent were excluded from study. Demographic data and tests results (CD4 and CrAg) were collected using a standardized form.

Discussion

This is the first study evaluating the CrAg positivity rate among PLHIV with CD4 cell counts <200 cell/mm\(^3\) in Haiti. CrAg prevalence among patients with CD4 cell counts <200 cell/mm\(^3\) from 28 health facilities providing HIV care and treatment was low (1.1%). In light of the 2011 WHO Rapid advice: diagnosis, prevention and management of cryptococcal disease in HIV infected adults, adolescents and children [16], routine CrAg screening and treatment may not be warranted on the basis of these findings. However, several reports, including more recent evidence, have indicated that a screen and treat approach may be cost-effective at a prevalence as low as 0.6%. New guidelines from WHO will update the prevalence cut-off for routine CrAg screening in ART-naive adults since the 2011 recommendations were based on latex agglutination assay and data from LFA suggest test and treat approach might be effective at prevalence levels as low as 0.6% [9,11,18]. In other RLC, asymptomatic antigenemia has been documented from between 4 to 12% of PLHIV initiating ART [5,10,11] which is quite high compared to our findings. During the eight month study period, only 7.9% (1,025 out of 13,000) of the patients met the criteria of a CD4 cell count <200 cells/mm\(^3\) to participate in the study. The high proportion of patients with CD4 cell counts >200 cells/mm\(^3\) suggests that PLHIV in Haiti tend to initiate ART at early stages of infection, thus lowering their risk for cryptococcal infection.

| Variable | Result |
|----------|--------|
| Patient samples included, # | 1025 |
| Gender, #, [% (95% CI)]* | | |
| Female | 581 (59.3 [56.2 – 62.4]) |
| Male | 439 (40.7 [37.6 – 43.8]) |
| Age, median (min - max) (IQR) years* | 39 (18 - 83) [31 - 47] |
| Age group, #, [% (95% CI)] | | |
| 18-28 years | 170 (17.4 [15 – 19.8]) |
| 1-39 years | 336 (34.4 [31.4 – 37.4]) |
| 40-50 years | 286 (30.3 [27.4 – 33.2]) |
| >50 years | 174 (17.8 [15.4 – 20.2]) |
| ART status, #, [% (95% CI)]* | | |
| Pre-ART | 198 (20.0 [17.5 – 22.5]) |
| ART | 723 (80.0 [77.5 – 82.5]) |
| CD4 result, median (IQR) cells/ mm\(^3\) | 87 (39 - 150) |
| CD4 result strata, #, [% (95% CI)] | | |
| <100 cells/ mm\(^3\) | 585 (57.3 [54.3 -60.3]) |
| 100 - 200 cells/ mm\(^3\) | 436 (42.7 [39.7 – 45.7]) |

*data on gender missing from 45 patients
*data on age missing from 49 patients
*data on Antiretroviral treatment (ART) status missing from 34 patients
*data on CD4 result missing from 4 patients

Table 1: Patient demographic and clinical characteristics.
It is also clear that early access to ART is unlikely to entirely explain the low prevalence of CrAg observed in this study. CrAg screening and pre-emptive treatment with fluconazole in PLHIV who are CrAg positive has primarily targeted ART-naive patients, but some reports have demonstrated high prevalence of CrAg among patients receiving ART and at higher CD4 cell count ranges [19,22]. WHO recommends to consider routine serum or plasma CrAg screening in ART-naive adults [16], but it might be worthwhile to establish the prevalence of cryptococcus in patients already on ART who are failing therapy with low CD4 cell count (<100 cells/mm³) [19]. These findings also reinforce the fact that ART alone is insufficient treatment for CrAg positivity [5,10,23]. In September 2015, WHO issued new HIV treatment guidelines recommending treatment for all, regardless of CD4 cell count [24]. These early-release guidelines don’t address cryptococcus infection among PLHIV, but updates should be provided to clarify the role of CD4 testing and CrAg screening and pre-emptive treatment in the HIV test and treat era.

Conclusion

Further research based on nationally representative sampling of patients with CD4 cell count <100 cells/mm³ is needed to determine the national prevalence of serum CrAg among PLHIV or to determine if there is geographic variation, to further inform national policies on CrAg screening. Cost-effectiveness studies are needed to inform and update international normative guidance. Ideally, these will be carried out within a HIV “test and treat” model.

References

1. Bicanic T, Harrison TS (2005) Cryptococcal meningitis. Br Med Bull 72: 99-118.
2. Park BJ, Wannemuehler KA, Marston BJ, Govender N, Pappas PG, et al. (2009) Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS 23: 525-530.
3. Rajasingham R, Rolfs MA, Birkenkamp KE, Meya DB, Boulware DR (2012) Cryptococcal meningitis treatment strategies in resource-limited settings: a cost-effectiveness analysis. PLoS Med 9: e1001318.
4. Okongo M, Morgan D, Mayanja B, Ross A, Whitworth J (1998) Causes of death in a rural, population-based human immunodeficiency virus type 1 (HIV-1) natural history cohort in Uganda. Int J Epidemiol 27: 698-702.
5. Jarvis JN, Lawn SD, Vogt M, Bangani N, Wood R, et al. (2009) Screening for cryptococcal antigenemia in patients accessing an antiretroviral treatment program in South Africa. Clin Infect Dis 48: 856-862.
6. Corbett EL, Churchyard GJ, Charlambous S, Samb B, Moloi V, et al. (2002) Morbidity and mortality in South African gold miners: impact of untreated disease due to human immunodeficiency virus. Clin Infect Dis 34: 1251-1258.
7. French N, Gray K, Watiera C, Nakiyingi J, Lugada E, et al. (2002) Cryptococcal infection in a cohort of HIV-1-infected Ugandan adults. AIDS 16: 1031-1038.
8. Deschamps MM, Fitzgerald DW, Pape JW, Johnson WD Jr (2000) HIV infection in adults: natural history and disease progression. AIDS 14: 2515-2521.
9. Jarvis JN, Harrison TS, Lawn SD, Meintjes G, Wood R, et al. (2013) Cost effectiveness of cryptococcal antigen screening as a strategy to prevent HIV-associated cryptococcal meningitis in South Africa. PLoS One 8: e69288.
10. Liechty CA, Bolger P, Were W, Ekwaru JP, Ransom RL, et al. (2007) Asymptomatic serum cryptococcal antigenemia and early mortality during antiretroviral therapy in rural Uganda. Trop Med Int Health 12: 929-935.
11. Micol R, Lortholary O, Sar B, Laureillard D, Ngeth C, et al. (2007) Prevalence, determinants of positivity, and clinical utility of cryptococcal antigenemia in Cambodian HIV-infected patients. J Acquir Immune Defic Syndr 45: 555-559.
12. Oyella J, Meza D, Bajurinrve F, Kamya MR (2012) Prevalence and factors associated with cryptococcal antigenemia among severely immunosuppressed HIV-infected adults in Uganda: a cross-sectional study. J Int AIDS Soc 15: 15.
13. Govender NP, Chetty V, Roy M, Chiller T, Oladoyinbo S, et al. (2012) Phased implementation of screening for cryptococcal disease in South Africa. S Afr Med J 102: 914-917.
14. McMullan BJ, Halliday C, Sorrell TC, Judd D, Sleiman S, et al. (2012) Clinical utility of the cryptococcal antigen lateral flow assay in a diagnostic mycology laboratory. PLoS One 7: e49541.
15. Meyer AC, Kendi CK, Penner JA, Odihambo N, Olteno B, et al. (2013) The impact of routine cryptococcal antigen screening on survival among HIV-infected individuals with advanced immunosuppression in Kenya. Trop Med Int Health 18: 495-503.
16. World Health Organization (WHO) (2014) Rapid advice: Diagnosis, Prevention and Management of Cryptococcal Disease in HIV-infected Adults, Adolescents and Children.
17. Rajasingham R, Meya DB, Boulware DR (2012) Integrating cryptococcal antigen screening and pre-emptive treatment into routine HIV care. J Acquir Immune Defic Syndr 59: e85-91.
18. Smith RM, Nguyen TA, Ha HT, Thang PH, Thuy C, et al. (2013) Prevalence of cryptococcal antigenemia and cost-effectiveness of a cryptococcal antigen screening program--Vietnam. PLoS One 8: e62213.
19. Alemu AS, Kempker RR, Tenna A, Smirlom C, Berhe N, et al. (2013) High prevalence of Cryptococcal antigenemia among HIV-infected patients receiving antiretroviral therapy in Ethiopia. PLoS One 8: e58377.
20. Martins LM, Wanke B, Zalena Mdo S, Trilles L, Barbossa GG, et al. (2011) Genotypes of Cryptococcus neoformans and Cryptococcus gattii as agents of endemic cryptococciosis in Teresina, Piauí (northeastern Brazil). Mem Inst Oswaldo Cruz 106: 725-730.
21. Jean Louis F, Osborne AJ, Elias VJ, Butau J, Boncy J, et al. (2015) Specimen Referral Network to Rapidly Scale-Up CD4 Testing: The Hub and Spoke Model for Haiti. J AIDS Clin Res 6: 488.
22. Abubakar AO, Maikai BV, Musa BO, Olayinka AT (2014) Public Health Implications of Cryptococcal Infection among HIV Patients on Antiretroviral Therapy in Hospital in Shika, Nigeria. Online Journal of Public Health Informatics 6: e61.
23. Meya DB, Manabe YC, Castelnovuo B, Cock BA, Elbreer AM, et al. (2010) Cost-effectiveness of serum cryptococcal antigen screening to prevent deaths among HIV-infected persons with a CD4+ cell count < or = 100 cells/microl, who start HIV therapy in resource-limited settings. Clin Infect Dis 51: 448-455.
24. World Health Organization (WHO) (2015) Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV.